Featured Publications
Pharmacological and behavioral treatment for trichotillomania: An updated systematic review with meta‐analysis
Farhat LC, Olfson E, Nasir M, Levine JLS, Li F, Miguel EC, Bloch MH. Pharmacological and behavioral treatment for trichotillomania: An updated systematic review with meta‐analysis. Depression And Anxiety 2020, 37: 715-727. PMID: 32390221, DOI: 10.1002/da.23028.Peer-Reviewed Original ResearchConceptsClinical trialsSingle randomized clinical trialTTM symptomsFirst-line medicationRandomized clinical trialsStrong evidence baseLarge treatment effectsHair pulling disorderEffective medicationsAvailable agentsPharmacological agentsAdditional trialsDrug AdministrationPsychiatric conditionsSystematic reviewN-acetylcysteineBehavioral treatmentBehavioral therapyEvidence baseTrichotillomaniaTrialsRelative efficacyTreatment effectsMedicationsSymptomsMeta-Analysis: Treatment of Attention-Deficit/Hyperactivity Disorder in Children With Comorbid Tic Disorders
Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-Analysis: Treatment of Attention-Deficit/Hyperactivity Disorder in Children With Comorbid Tic Disorders. Journal Of The American Academy Of Child & Adolescent Psychiatry 2009, 48: 884-893. PMID: 19625978, PMCID: PMC3943246, DOI: 10.1097/chi.0b013e3181b26e9f.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic alpha-AgonistsAtomoxetine HydrochlorideAttention Deficit Disorder with HyperactivityChildComorbidityContraindicationsDose-Response Relationship, DrugDouble-Blind MethodHumansMethylphenidatePropylaminesPsychotropic DrugsRandomized Controlled Trials as TopicTic DisordersTourette SyndromeConceptsAlpha-2 agonistsAttention-deficit/hyperactivity disorderTic symptomsComorbid ticsSupratherapeutic dosesTic disordersADHD symptomsTreatment of ADHDHyperactivity disorderPlacebo-controlled trialEfficacy of medicationsStandardized mean differenceEvidence-based treatmentsHalf of childrenComorbid tic disordersPrimary outcomeDifferent medicationsPsychostimulant medicationPubMed searchTic severityTourette syndromePackage insertsDrug AdministrationAtomoxetineSymptomsTreatment Outcomes With Licensed and Unlicensed Stimulant Doses for Adults With Attention-Deficit/Hyperactivity Disorder
Farhat L, Flores J, Avila-Quintero V, Polanczyk G, Cipriani A, Furukawa T, Bloch M, Cortese S. Treatment Outcomes With Licensed and Unlicensed Stimulant Doses for Adults With Attention-Deficit/Hyperactivity Disorder. JAMA Psychiatry 2024, 81: 157-166. PMID: 37878348, PMCID: PMC10600727, DOI: 10.1001/jamapsychiatry.2023.3985.Peer-Reviewed Original ResearchAttention-deficit/hyperactivity disorderLicensed dosesDose-response curveStimulant dosesClinical trialsTreatment outcomesRisk benefitHyperactivity disorderReduction of symptomsDrug Administration recommendationsAdverse eventsDose escalationLanguage restrictionsAdministration recommendationsUS FoodSymptomsDosesAdditional riskData extractionAdditional reductionADHD symptomsAdultsGreater reductionStimulantsRisk
2018
Time course of clinical change following neurofeedback
Rance M, Walsh C, Sukhodolsky DG, Pittman B, Qiu M, Kichuk SA, Wasylink S, Koller WN, Bloch M, Gruner P, Scheinost D, Pittenger C, Hampson M. Time course of clinical change following neurofeedback. NeuroImage 2018, 181: 807-813. PMID: 29729393, PMCID: PMC6454268, DOI: 10.1016/j.neuroimage.2018.05.001.Peer-Reviewed Original ResearchConceptsClinical changesSymptom changeTime courseBrain functionNeurofeedback studiesPotential clinical toolCrossover designControl interventionsReal neurofeedbackClinical toolTime pointsClinical populationsNeurofeedback effectsInterventionNeurofeedback sessionsNeurofeedbackCurrent brain stateWeeksBrain statesNew studiesCourseSessionsSymptomsChapter 17 Managing a Child With OCD Who Is Treatment Refractory
Bloch M. Chapter 17 Managing a Child With OCD Who Is Treatment Refractory. 2018, 329-356. DOI: 10.1016/b978-0-12-811427-8.00017-4.Peer-Reviewed Original ResearchObsessive-compulsive disorderTreatment-refractory obsessive-compulsive disorderCognitive behavioral therapyFirst-line treatmentOCD symptomsPediatric obsessive-compulsive disorderSelective serotonin reuptake inhibitor (SSRI) pharmacotherapyEffective first-line treatmentSelective serotonin reuptake inhibitorsIntensive treatment programSerotonin reuptake inhibitorsGlutamate-modulating agentsMajority of childrenTreatment programAntipsychotic augmentationReuptake inhibitorsTreatment refractoryPharmacological treatmentAvailable treatmentsChildrenSubstantial proportionPharmacotherapyTreatmentTherapySymptoms
2015
Meta-Analysis: Reduced Risk of Anxiety with Psychostimulant Treatment in Children with Attention-Deficit/Hyperactivity Disorder
Coughlin CG, Cohen SC, Mulqueen JM, Ferracioli-Oda E, Stuckelman ZD, Bloch MH. Meta-Analysis: Reduced Risk of Anxiety with Psychostimulant Treatment in Children with Attention-Deficit/Hyperactivity Disorder. Journal Of Child And Adolescent Psychopharmacology 2015, 25: 611-617. PMID: 26402485, PMCID: PMC4617411, DOI: 10.1089/cap.2015.0075.Peer-Reviewed Original ResearchConceptsRisk of anxietyAttention-deficit/hyperactivity disorderPsychostimulant treatmentSide effectsHyperactivity disorderPlacebo-controlled trialStratified subgroup analysisTreatment of childrenDuration of useRisk ratioSubgroup analysisPsychostimulant medicationPlaceboPubMed searchTrial designNumber of childrenHigh dosesStimulant typePsychostimulantsAnxiety symptomsTreatmentChildrenRiskSymptomsAnxietyLONG‐TERM OUTCOME IN PEDIATRIC TRICHOTILLOMANIA
Schumer MC, Panza KE, Mulqueen JM, Jakubovski E, Bloch MH. LONG‐TERM OUTCOME IN PEDIATRIC TRICHOTILLOMANIA. Depression And Anxiety 2015, 32: 737-743. PMID: 26139231, PMCID: PMC4591183, DOI: 10.1002/da.22390.Peer-Reviewed Original ResearchConceptsPoor long-term prognosisLong-term prognosisLong-term outcomesN-acetylcysteineDepressive symptomsPediatric trichotillomaniaTrichotillomania symptomsOlder ageAdequate symptom reliefPlacebo-controlled trialAnxiety symptomsPredictors of outcomePrevious cross-sectional studiesRisk of depressionCross-sectional studyPrimary outcomeSymptom reliefAcute phaseClinical assessmentTreatment utilizationBaseline evaluationSecondary measuresBaseline assessmentSymptomsBehavioral treatmentObsessive-compulsive symptom dimensions in a population-based, cross-sectional sample of school-aged children
Alvarenga PG, Cesar RC, Leckman JF, Moriyama TS, Torres AR, Bloch MH, Coughlin CG, Hoexter MQ, Manfro GG, Polanczyk GV, Miguel EC, do Rosario MC. Obsessive-compulsive symptom dimensions in a population-based, cross-sectional sample of school-aged children. Journal Of Psychiatric Research 2015, 62: 108-114. PMID: 25702286, DOI: 10.1016/j.jpsychires.2015.01.018.Peer-Reviewed Original ResearchConceptsSchool-aged childrenPsychiatric symptomsFamily History ScreenAdditional clinical factorsSymptom dimensionsCommunity-based sampleObsessive-compulsive symptom dimensionsClinical factorsObsessive-compulsive disorderPsychiatric comorbidityClinical impairmentSchool impairmentCross-sectional sampleAge 6Clinical samplesFamilial aggregationBiological mothersChildrenBiological relativesSymptomsPrevalenceAge distributionImpairmentNon-clinical samplePresent study
2014
Nutritional Supplements for the Treatment of ADHD
Bloch MH, Mulqueen J. Nutritional Supplements for the Treatment of ADHD. Child And Adolescent Psychiatric Clinics Of North America 2014, 23: 883-897. PMID: 25220092, PMCID: PMC4170184, DOI: 10.1016/j.chc.2014.05.002.Peer-Reviewed Original ResearchConceptsSide effectsNatural supplementsFatty acid supplementationADHD symptomsCore ADHD symptomsPossible side effectsTreatment of ADHDChronic insomniaADHD treatmentAcid supplementationModest benefitPotential efficacyNutritional supplementsHerbal remediesScientific evidenceMinimal evidenceSymptomsEfficacySupplementsMeta-analysis: hoarding symptoms associated with poor treatment outcome in obsessive–compulsive disorder
Bloch MH, Bartley CA, Zipperer L, Jakubovski E, Landeros-Weisenberger A, Pittenger C, Leckman JF. Meta-analysis: hoarding symptoms associated with poor treatment outcome in obsessive–compulsive disorder. Molecular Psychiatry 2014, 19: 1025-1030. PMID: 24912494, PMCID: PMC4169729, DOI: 10.1038/mp.2014.50.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderTreatment responseOCD patientsOdds ratioFurther treatment researchCase-control studyPoor treatment outcomesDifferential treatment responseSymptoms of OCDPrimary outcomeTreatment modalitiesEligible studiesTreatment outcomesPatientsElectronic searchSymptomsTotal participantsBehavioral therapyOCD treatmentDisordersSymptom dimensionsTreatment researchDSM-5Hoarding symptomsTreatment
2013
Systematic Review and Meta-analysis of Pharmacological Treatment of the Symptoms of Attention-Deficit/Hyperactivity Disorder in Children with Pervasive Developmental Disorders
Reichow B, Volkmar FR, Bloch MH. Systematic Review and Meta-analysis of Pharmacological Treatment of the Symptoms of Attention-Deficit/Hyperactivity Disorder in Children with Pervasive Developmental Disorders. Journal Of Autism And Developmental Disorders 2013, 43: 2435-2441. PMID: 23468071, PMCID: PMC3787525, DOI: 10.1007/s10803-013-1793-z.Peer-Reviewed Original ResearchConceptsAttention-deficit/hyperactivity disorderADHD symptomsTrial of atomoxetineHyperactivity disorderPlacebo-controlled trialEfficacy of medicationsAdverse eventsPharmacological treatmentMethylphenidate trialMeta-AnalysisSystematic reviewSymptomsPervasive developmental disorderTrialsRelative efficacyIndividual trialsMedicationsDisordersChildrenDevelopmental disordersEfficacyPDDRandom effectsPlaceboClonidineAge and Gender Correlates of Pulling in Pediatric Trichotillomania
Panza KE, Pittenger C, Bloch MH. Age and Gender Correlates of Pulling in Pediatric Trichotillomania. Journal Of The American Academy Of Child & Adolescent Psychiatry 2013, 52: 241-249. PMID: 23452681, PMCID: PMC3745006, DOI: 10.1016/j.jaac.2012.12.019.Peer-Reviewed Original ResearchConceptsFrequent urgesCommon comorbid conditionsPediatric trichotillomaniaProspective longitudinal studyType of treatmentCross-sectional findingsClinical characteristicsComorbid conditionsStructured rating scaleTreatment trialsComorbid depressionRating ScaleAnxiety disordersOlder childrenTrichotillomaniaDecreased abilityLongitudinal studyMale participantsAgeChildrenGreater distressFemale participantsLower ratesSymptomsGender correlatesSymptom dimensions are associated with age of onset and clinical course of obsessive–compulsive disorder
Kichuk SA, Torres AR, Fontenelle LF, Rosário MC, Shavitt RG, Miguel EC, Pittenger C, Bloch MH. Symptom dimensions are associated with age of onset and clinical course of obsessive–compulsive disorder. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2013, 44: 233-239. PMID: 23410525, PMCID: PMC3654083, DOI: 10.1016/j.pnpbp.2013.02.003.Peer-Reviewed Original ResearchConceptsAge of onsetClinical courseObsessive-compulsive disorderPrimary symptom dimensionsSymptom dimensionsPrimary OCD symptomsChi-square testEarly ageOCD symptom dimensionsYale-Brown ObsessiveAdult patientsComorbid ticsSignificant symptomsLarge cohortDifferent OCD symptom dimensionsHeterogeneous symptomsSymptomsCompulsive ScaleDimensional Yale-Brown ObsessiveAgeSignificant differencesOCD symptomsOnsetInconsistent resultsRelationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans
Driesen NR, McCarthy G, Bhagwagar Z, Bloch M, Calhoun V, D'Souza DC, Gueorguieva R, He G, Ramachandran R, Suckow RF, Anticevic A, Morgan PT, Krystal JH. Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. Molecular Psychiatry 2013, 18: 1199-1204. PMID: 23337947, PMCID: PMC3646075, DOI: 10.1038/mp.2012.194.Peer-Reviewed Original ResearchConceptsFunctional connectivityNegative symptomsGamma-aminobutyric acid (GABA) neuronsNMDA receptor antagonist ketamineAspartate glutamate receptor antagonistContinuous ketamine infusionGlutamate receptor antagonistsNMDA-R antagonistsCortical functional connectivityNMDA-R antagonist ketamineSchizophrenia-like symptomsHealthy human subjectsNegative Syndrome ScaleBrain functional connectivityPrimary samplesRegion-specific mannerFunctional magnetic resonanceKetamine infusionReceptor antagonistPathological increaseSyndrome ScaleSymptomsPreclinical researchKetamineBrain oscillations
2010
Predictors of early adulthood quality of life in children with obsessive–compulsive disorder
Palermo SD, Bloch MH, Craiglow B, Landeros-Weisenberger A, Dombrowski PA, Panza K, Smith ME, Peterson BS, Leckman JF. Predictors of early adulthood quality of life in children with obsessive–compulsive disorder. Social Psychiatry And Psychiatric Epidemiology 2010, 46: 291-297. PMID: 20191262, PMCID: PMC3645906, DOI: 10.1007/s00127-010-0194-2.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderEarly adulthoodOCD symptomsImpaired Functioning ToolMethodsA longitudinal cohort studyLongitudinal cohort studyResultsForty-two percentSeverity of OCDAverage followClinical predictorsCohort studyPoor QoLResidual impairmentMild impairmentQoLSymptomsObjectivesThe goalAnxiety symptomsAdulthoodChildrenQoL.ChildhoodHoarding symptomsImpairmentDisorders
2009
Clinical course of Tourette syndrome
Bloch MH, Leckman JF. Clinical course of Tourette syndrome. Journal Of Psychosomatic Research 2009, 67: 497-501. PMID: 19913654, PMCID: PMC3974606, DOI: 10.1016/j.jpsychores.2009.09.002.Peer-Reviewed Original ResearchConceptsTourette syndromeComorbid conditionsObsessive-compulsive disorderClinical courseLong-term clinical courseChildhood-onset neuropsychiatric disorderEarly adulthoodLong-term outcomesAttention deficit disorderTic symptomsDepressive disorderTic disordersVocal ticsGeneral populationNeuropsychiatric disordersLiterature searchRelevant articlesDisordersSyndromeChildrenAdulthood outcomesOne-thirdSymptomsTraditional literature searchThree-quartersDimensional predictors of response to SRI pharmacotherapy in obsessive–compulsive disorder
Landeros-Weisenberger A, Bloch MH, Kelmendi B, Wegner R, Nudel J, Dombrowski P, Pittenger C, Krystal JH, Goodman WK, Leckman JF, Coric V. Dimensional predictors of response to SRI pharmacotherapy in obsessive–compulsive disorder. Journal Of Affective Disorders 2009, 121: 175-179. PMID: 19577308, PMCID: PMC3974618, DOI: 10.1016/j.jad.2009.06.010.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderSRI responseSymptom dimensionsOpen-label continuation phaseClinical Global Improvement ScaleGlobal Improvement ScaleCentral serotonin systemInitial positive responseYale-Brown ObsessiveContinuation phaseMinor symptomsOrdinal logistic regressionClinical trialsSerotonin systemTreatment responseSame patientImprovement ScaleSRI treatmentPatientsSignificant associationLogistic regressionCompulsive ScaleOCD patientsOCD subjectsSymptoms
2008
Emerging treatments for Tourette’s disorder
Bloch MH. Emerging treatments for Tourette’s disorder. Current Psychiatry Reports 2008, 10: 323. PMID: 18627671, DOI: 10.1007/s11920-008-0052-z.Peer-Reviewed Original ResearchConceptsTourette's disorderRepetitive transcranial magnetic stimulationChildhood-onset neuropsychiatric disorderHabit reversal therapyDeep brain stimulationTranscranial magnetic stimulationReversal therapyVocal ticsCurrent treatmentSevere symptomsMagnetic stimulationBrain stimulationSignificant disabilityNeuropsychiatric disordersEvidence baseDisordersTreatmentStimulationTherapySymptomsMultiple motors
2005
Caudate volumes in childhood predict symptom severity in adults with Tourette syndrome
Bloch MH, Leckman JF, Zhu H, Peterson BS. Caudate volumes in childhood predict symptom severity in adults with Tourette syndrome. Neurology 2005, 65: 1253-1258. PMID: 16247053, PMCID: PMC2367161, DOI: 10.1212/01.wnl.0000180957.98702.69.Peer-Reviewed Original ResearchConceptsSeverity of ticsBasal ganglia volumesCaudate nucleus volumeTourette syndromeObsessive-compulsive symptomsGanglia volumesEarly adulthoodObsessive-compulsive disorderTic symptomsCaudate nucleusCaudate volumeCross-sectional imaging studiesThalamo-cortical circuitsNucleus volumeSeverity of symptomsAge 16 yearsProspective longitudinal studyAge 14 yearsClinical statusClinical assessmentClinical measuresMorphologic disturbancesMRI scansSymptomsImaging studies